Henry Schein, Inc. (HSIC) Updates FY18 Earnings Guidance

Lloyd Doyle
November 9, 2017

Henry Schein, Inc.'s RSI is 27.37. Institutional ownership is usually beneficial to a stock price initially, but very high institutional ownership has several shortcomings. Henry Schein Inc. had 37 analyst reports since July 31, 2015 according to SRatingsIntel. RAS share have plunged by -89.29% in percentage terms since the start of the year - and retreated -47.1% in the last month. On Friday, September 15 the stock rating was maintained by UBS with "Buy". The rating was maintained by Roth Capital on Monday, March 14 with "Buy". The company was maintained on Wednesday, October 25 by Robert W. Baird.

The PEG for Henry Schein, Inc.is gauging a 2.07, signposting the future growth of the company's earnings. (NASDAQ:HSIC) on Tuesday, January 10 to "Buy" rating.

Henry Schein declared that its Board of Directors has initiated a share repurchase program on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. On Tuesday, November 7 the stock rating was maintained by Stifel Nicolaus with "Hold". (NASDAQ:HSIC) on Thursday, November 5 with "Outperform" rating. The company was upgraded on Tuesday, October 11 by Goldman Sachs. Rhenman & Partners Asset Management Ab sold 50,000 shares as Halozyme Therapeutics Inc (HALO)'s stock rose 2.38%. HSIC's average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of HSIC's future price movements. Halozyme Therapeutics Inc now has $2.41B valuation. The stock increased 0.64% or $0.21 during the last trading session, reaching $33.07. New Relic Inc (NYSE:NEWR) has risen 65.48% since November 8, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.

Invesco Ltd increased Apollo Coml Real Est Fin Inc (NYSE:ARI) stake by 746,166 shares to 1.13M valued at $20.90M in 2017Q2.


Media headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive this week, Accern Sentiment Analysis reports. It has underperformed by 16.70% the S&P500. The company has market cap of $11.23 billion. The Company's segments include healthcare distribution, and technology and value-added services. The powerful forward P/E ratio allows investors a quick snapshot of the organization's finances without getting involved in the complicated details of the accounting report. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment fix services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

As of now, Henry Schein, Inc. has a P/S value of 0.92, measuring P/B at 3.78. It is positive, as 31 investors sold HSIC shares while 164 reduced holdings. Its up 0.81, from 1.35 in 2017Q1. Investors use this ratio to decide what multiple of earnings a share is worth. 60 funds opened positions while 166 raised stakes. Suntrust Banks holds 0.01% or 11,864 shares. Pittenger Anderson Inc has invested 0.63% of its portfolio in Henry Schein, Inc.

Henry Schein, Inc., that has shown a discernible change in trend levels over the path of recent market activity. Wetherby Asset Mngmt Incorporated holds 3,235 shares or 0.1% of its portfolio. Guggenheim Ltd Liability Corporation reported 236,418 shares or 0.11% of all its holdings. Any way you dice it, a dip below $68.09 a share would be very bad news for HSIC's technical picture in the near-term. Commonwealth Natl Bank Of Aus accumulated 5,873 shares or 0.01% of the stock. The stock of AT&T Inc. (NASDAQ:HSIC) for 9,669 shares. Burt Wealth Advsrs reported 128 shares. 159,392 are held by Rhumbline Advisers. Therefore 75% are positive. The firm has "Hold" rating by RBC Capital Markets given on Monday, October 2. The stock of Halozyme Therapeutics, Inc. Piper Jaffray maintained Halozyme Therapeutics, Inc. The firm has "Hold" rating by Craig Hallum given on Wednesday, April 12. Stifel Nicolaus has "Hold" rating and $17800 target. Citigroup downgraded Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Friday, January 6 to "Neutral" rating. Jefferies has "Hold" rating and $17700 target. Also, EVP Mark E. Mlotek sold 2,417 shares of Henry Schein stock in a transaction dated Thursday, November 3rd. Fortive Corp was reduced too. 3,550 are held by Laurel Grove Ltd Limited Liability Company. Credit Suisse Ag stated it has 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Paradigm Capital Ny holds 0.01% or 10,000 shares. The original version of this report can be accessed at http://www.financial-market-news.com/henry-schein-inc-hsic-shares-sold-by-state-treasurer-state-of-michigan/1204932/. Meeder Asset Mgmt holds 0% or 514 shares. (NASDAQ:HALO). Secor Cap Limited Partnership has 0.11% invested in Halozyme Therapeutics, Inc. Fmr has invested 0.01% in Halozyme Therapeutics, Inc.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER